A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of HRS-3095 in Healthy Participants
Interventional Start Date: July 30, 2026
End Date: October 15, 2026
32 days until trial ends
